Lauper K, et al. - Researchers compared the efficacy of tocilizumab (TCZ) and tumour necrosis factor (TNF) inhibitors (TNFi) as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) after the use of at least one biologic DMARD (bDMARD). Findings suggested that in patients with inadequate response to at least one bDMARD, TCZ mono or combo are reasonable therapeutic options with significantly longer drug retention and similar efficacy to TNFi combo. Similar average adjusted Clinical Disease Activity Index (CDAI) change was seen between groups. Authors noted comparable CDAI remission and low disease activity (LDA) rates between groups.